Randall Brenner - Paratek Pharmaceuticals Chief Officer
| PRTKDelisted Stock | USD 2.18 0.00 0.00% |
Insider
Randall Brenner is Chief Officer of Paratek Pharmaceuticals
| Age | 50 |
| Phone | 617 807 6600 |
| Web | https://paratekpharma.com |
Paratek Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Paratek Pharmaceuticals' management efficiency ratios could be used to measure how well Paratek Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Paratek Pharmaceuticals currently holds 258.41 M in liabilities with Debt to Equity (D/E) ratio of 3.2, implying the company greatly relies on financing operations through barrowing. Paratek Pharmaceuticals has a current ratio of 3.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Paratek Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Walter Newman | Leap Therapeutics | 78 | |
| Joel Rothman | Equillium | 55 | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Janet CA | Aptose Biosciences | N/A | |
| Christine MBA | Hookipa Pharma | 59 | |
| Christine Granfield | Leap Therapeutics | 56 | |
| Margaret Henry | Adaptimmune Therapeutics Plc | N/A | |
| Kevin MD | Jasper Therapeutics | 53 | |
| Christian Mueller | Immutep Ltd ADR | N/A | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| Angus Smith | Affimed NV | 42 | |
| Krishna MD | Equillium | 51 | |
| Pr Little | Affimed NV | N/A | |
| Juli Miller | Adaptimmune Therapeutics Plc | N/A | |
| Uwe Reusch | Affimed NV | N/A | |
| Helen MBA | Adaptimmune Therapeutics Plc | 57 | |
| Denise Mueller | Affimed NV | 54 | |
| Andreas MD | Affimed NV | 63 | |
| Augustine Lawlor | Leap Therapeutics | 67 | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
Management Performance
| Return On Asset | -0.18 |
Paratek Pharmaceuticals Leadership Team
Elected by the shareholders, the Paratek Pharmaceuticals' board of directors comprises two types of representatives: Paratek Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paratek. The board's role is to monitor Paratek Pharmaceuticals' management team and ensure that shareholders' interests are well served. Paratek Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paratek Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Ex Chairman | ||
| FACC FAHA, CEO Director | ||
| Karen McGrath, VP HR | ||
| Sarah Higgins, Interim Principal Financial Officer and Principal Accounting Officer | ||
| Ben Strain, VP CEO | ||
| William Haskel, Senior Vice President General Counsel, Corporate Secretary | ||
| Adam Woodrow, Vice President and Chief Commercial Officer | ||
| Jason Burdette, VP Operations | ||
| Randall Brenner, Chief Officer |
Paratek Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Paratek Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 345.3 M | |||
| Shares Outstanding | 57.32 M | |||
| Shares Owned By Insiders | 11.70 % | |||
| Shares Owned By Institutions | 55.08 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Earning | (5.49) X | |||
| Price To Sales | 0.86 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |